DFDA

Linezolid (as part of regimens)

Treatment for Extensively Drug Resistant Tuberculosis

Typical Dosage: 300-600mg daily

Effectiveness
75%
Safety Score
35%
Clinical Trials
40
Participants
5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
300-600mg daily
Time to Effect
3-6 months
Treatment Duration
6-24 months
Evidence Quality
MODERATE
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$3,000
Side Effect Mgmt:$4,500
Total Annual:$9,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$35,000/QALY
QALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$13,571
Cost per Remission
$13,571
Comparison vs Less effective older XDR-TB regimens
Cost Difference
+$2,000/year
More expensive
QALY Difference
+0.60 QALYs
Better outcomes
Dominance
No dominance
Linezolid (as part of regimens) Outcomes

for Extensively Drug Resistant Tuberculosis

Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+70%
Remission Rate
+70%
Common Side Effects
Peripheral neuropathy
+50%
Myelosuppression (anemia, thrombocytopenia)
+15%
Optic neuritis
+7%
Gastrointestinal intolerance
+15%

Sources:

nih.gov
msf.org
msf.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov